Enhancing GI Tolerability of GLP-1 Receptor Agonists: A Path to Improved Therapeutic Outcomes

GLP-1 Receptor Agonists (GLP-1 RAs):
These drugs are used to treat type 2 diabetes and obesity by mimicking the action of the incretin hormone glucagon-like peptide-1, which helps regulate blood sugar levels and promotes satiety.

GI Tolerability Issues:
Common gastrointestinal adverse events associated with GLP-1 RAs include nausea, vomiting, diarrhea, and constipation, affecting up to 85% of treated patients.

Strategies for Improving GI Tolerability:

Gradual Dose Titration:
Starting with lower doses and gradually increasing them can help mitigate GI side effects.

Dietary Adjustments:
Comprehensive dietary education and flexibility during dose escalation can minimize GI adverse events.

Symptomatic Treatment:
Appropriate management of persistent GI symptoms is crucial for patient compliance.

Alternative Dosing Strategies:
For patients who miss doses, reinitiating therapy at a lower dose can help reduce GI intolerance.

Emerging Therapeutic Approaches:
Research into novel GLP-1 RAs and combination therapies aims to improve efficacy and tolerability, including the development of dual GLP-1/GIP receptor agonists like tirzepatide.

Neurogastrx’s Initiative:
The company aims to enhance GI tolerability of GLP-1 RAs, potentially through innovative formulations or adjunctive therapies, to improve patient outcomes and adherence to treatment.